fat-binder: Weight Regain After Consumption of Food Supplement and Interventional Diet Program

Sponsor
Instituto de Investigación Hospital Universitario La Paz (Other)
Overall Status
Completed
CT.gov ID
NCT03554525
Collaborator
(none)
120
1
2
20
6

Study Details

Study Description

Brief Summary

Effect of the dietary supplement (FAT-BINDER DAMM) on weight regain after 9 months of control weight program

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Fat-binder damm
  • Dietary Supplement: Placebo
Phase 3

Detailed Description

  • 60 participants will consume experimental product every day 3 sticks of the dietary supplement (1.4 grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner. During the 12 first weeks, each volunteer will be included on a low weight program (PPP) with an individual hypocaloric diet planning and regular physical adapted activity (PPP period). When PPP period is over, volunteers will continue consuming the product for 9 months more (Post-PPP period).

  • 60 participants will consume everyday 3 placebo sticks (1.4 grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner. During the first 12 weeks, each volunteer will be included on a low weight program (PPP) with an individual hypocaloric diet planning and regular physical adapted activity (PPP period ). When PPP period is over, volunteers will continue consuming the product for 9 months more.

Study Design

Study Type:
Interventional
Actual Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Clinical Trial to Evaluate the Usefulness of the Regular Consumption of a Food Supplement(FAT-BINDER DAMM) on Weight Regain After an Interventional Diet Program on Overweight/Obese People
Actual Study Start Date :
Apr 1, 2017
Actual Primary Completion Date :
Dec 1, 2018
Actual Study Completion Date :
Dec 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental product : FAT-BINDER DAMM

3 sticks of the dietary supplement (1.4 grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.

Dietary Supplement: Fat-binder damm
3 sticks every day during 12 months

Placebo Comparator: Control product : PLACEBO

3 sticks of the dietary supplement (1.4grams/stick) during 12 months: 2 sticks should be consumed before lunch and 1 stick before dinner.

Dietary Supplement: Placebo
3 sticks every day during 12 months

Outcome Measures

Primary Outcome Measures

  1. Weight Regain [12 months]

    Change from baseline in kilograms

Secondary Outcome Measures

  1. Body Mass Index (weight/height^2) [12 months]

    Change from baseline in kg/m^2

  2. Fat mass percentage [12 months]

    Change from baseline in percentage

  3. Body water percentage [12 months]

    Change from baseline in percentage

  4. Lean mass percentage [12 months]

    Change from baseline in percentage

  5. Triglycerides [12 months]

    Change from baseline

  6. Low density lipoprotein cholesterol [12 months]

    Change from baseline

  7. High density lipoprotein cholesterol [12 months]

    Change from baseline

  8. Fiber [12 months]

    Change from baseline

  9. Satiety evaluation [[Just before eating the product; Just after eating; After 60 minutes; After 90 minutes] Fasting for at least 4 hours. Must do it with a snack accompanied and 500 ml water.]

    Visual Analog Scale to evaluate motivation-satiety when eating

  10. 24 hours Dietary Recall [12 months]

    24 hours Food habits of overweight and obesity people

  11. Sensory perception [Months 6, 7, 8 y 9. Gustatory and olfactory sensory perception of the subjects for the study products.]

    Questionnaire of analysis of sensory perception of the food study product. Five questions that are valued on a scale of 0% to 100% asking about the taste and smell of the study product: desire with which the product is taken, taste, smell, consistency and what wait for effectiveness.

  12. International Physical Activity Questionnaire [12 months]

    People physical activity habits

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Men and women ranging from 18 to 65 years old.

  • BMI ≥27 and <40 kg/m2. Overweight type II, obesity type I and II

  • Social or familiar environment that prevents from accomplishing the dietary treatment.

  • Willingness to follow a balanced hypocaloric diet in order to lose weight and perform regular physical adapted activity.

  • Adequate cultural level and understanding of the clinical trial.

  • Signed informed consent.

Exclusion Criteria:
  • Individuals diagnosed with Diabetes Mellitus type I.

  • Individuals diagnosed with Diabetes Mellitus type II on pharmacological treatment.

  • Individuals with dyslipidemia on pharmacological treatment.

  • Individuals with hypertension on pharmacological treatment uncontrolled.

  • Individuals allergic to yeast.

  • Individuals with chronic diseases (hepatic, kidney…).

  • Individuals who have participated in the last 6 months in a program or clinical trial to lose weight.

  • Individuals receiving at least the preceding 2 months a pharmacological treatment that modifies the lipid profile (for example, statins, fibrates, diuretics, corticosteroids, ADOs).

  • Pregnant or breastfeeding women.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institute for Health Research IdiPAZ Madrid Spain 28046

Sponsors and Collaborators

  • Instituto de Investigación Hospital Universitario La Paz

Investigators

  • Principal Investigator: Carmen Gómez Candela, PhD, MS, Hospital Universitario La Paz

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Instituto de Investigación Hospital Universitario La Paz
ClinicalTrials.gov Identifier:
NCT03554525
Other Study ID Numbers:
  • 4801
First Posted:
Jun 13, 2018
Last Update Posted:
Apr 17, 2019
Last Verified:
Apr 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Instituto de Investigación Hospital Universitario La Paz
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 17, 2019